Evidence map›Paper›PMID 41586866›Full record

ArticleInsights into imaging2026

Integrating deep learning with multimodal MRI habitat radiomics: toward personalized prediction of risk stratification and androgen deprivation therapy outcomes in prostate cancer.

Yun-Feng Zhang, Chuan Zhou, Jia Wang, Han He, Jie Yang, Wenbo Zhang, Hongde Hu, Qidong Wang, Wanbin He, Chao Wang and 3 more

Abstract read
In one paragraph

Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yun-Feng Zhang *The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Chuan Zhou *Department of Geriatric General Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Jia WangThe First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou, China.
Han HeThe First Clinical Medical College of Lanzhou University, Lanzhou, China.
Jie YangThe First Clinical Medical College of Lanzhou University, Lanzhou, China.
Wenbo ZhangThe First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou, China.
Hongde HuThe First Clinical Medical College of Lanzhou University, Lanzhou, China.
Qidong WangThe First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou, China.
Wanbin HeThe First Clinical Medical College of Lanzhou University, Lanzhou, China.
Chao WangThe First Clinical Medical College of Lanzhou University, Lanzhou, China.
Rong WangDepartment of Radiology, Gansu Provincial Hospital, Lanzhou, China.
Liming ZhaoDepartment of Urology, Second People's Hospital of Gansu Province, Lanzhou, China.
Fenghai ZhouThe First Clinical Medical College of Lanzhou University, Lanzhou, China. ldyy_zhoufh@lzu.edu.cn.ORCID http://orcid.org/0000-0001-9239-1683

Funding

Science and Technology Program of Gansu Province 25JRRA318
6 · The paper itself

Abstract

objectivesAndrogen deprivation therapy (ADT) is essential for treating prostate cancer (PCa) but is limited by tumor heterogeneity. This study develops a non-invasive multiparametric Magnetic Resonance Imaging (mpMRI) radiomics framework to predict ADT response and improve risk stratification. MATERIALS AND

methodsA cohort of 550 ADT-treated PCa patients from three centers was analyzed. Patients were randomly divided into training (n = 270) and internal validation (n = 115) cohorts. An external test cohort (n = 165) from Centers 2 and 3 was used for generalizability. Radiomics models based on T2-weighted and diffusion-weighted imaging (DWI), habitat radiomics, and a 3D Vision Transformer (ViT) deep learning model were developed. Ensemble integration of these models was performed, with SHapley Additive exPlanations (SHAP) used for interpretability. Predictive performance was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC).

resultsHabitat radiomics outperformed conventional radiomics in Gleason score stratification. For predicting ADT treatment efficacy, the radiomics model achieved AUCs of 0.969 (training), 0.767 (internal validation), and 0.771 (test). The habitat model showed AUCs of 0.987, 0.849, and 0.820, while the ViT model achieved AUCs of 0.831, 0.805, and 0.796. The ensemble model reached the highest AUC of 0.886. SHAP analysis shows that the ViT model contributes most to the combined model, followed by the habitat model, with the radiomics model contributing the least.

conclusionmpMRI-based habitat radiomics enables precise risk stratification in PCa. Integrated with conventional radiomics and deep learning, it forms a robust framework for predicting ADT response and guiding personalized treatment. CRITICAL RELEVANCE STATEMENT: This study demonstrates that integrating habitat radiomics with deep learning improves the prediction of androgen deprivation therapy response in PCa, advancing personalized radiological decision-making through interpretable multi-model analysis of tumor microenvironment heterogeneity. KEY POINTS: Multi-model integration of habitat radiomics and 3D Vision Transformer achieves superior prediction for ADT response compared to conventional methods. Habitat radiomics outperforms traditional radiomics in Gleason score stratification. SHAP analysis provides clinical interpretability, identifying key model linked to ADT outcomes for actionable insights.

Indexed as

Androgen deprivation therapyDeep learningHabitat radiomicsProstate cancer risk stratificationTherapeutic response assessment

Identifiers

PMID41586866
PMCPMC12834885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.